Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inference for cause-specific cox model absolute risk in cohort subsampling designs.

Lifetime data analysis·2026
Same author

Design aspects for prognostic factor studies.

BMJ open·2025
Same author

Breast Myofibroblastoma: A Single Institutional Case Series.

European journal of breast health·2025
Same author

Software Application Profile: CaseCohortCoxSurvival-an R package for case-cohort inference for relative hazard and pure risk under the Cox model.

International journal of epidemiology·2025
Same author

Disentangling discordant vitamin D associations with prostate cancer incidence and fatality in a large, nested case-control study.

International journal of epidemiology·2024
Same author

The utility and impact of digital endpoints for improving breast cancer outcomes.

Expert review of pharmacoeconomics & outcomes research·2024
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Related Experiment Video

Updated: Sep 6, 2025

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
13:35

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

2.9K

Tools for Contralateral Prophylactic Mastectomy Decision Making.

Mitchell H Gail1, Ismail Jatoi2

  • 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|June 27, 2022
PubMed
Summary
This summary is machine-generated.

Contralateral prophylactic mastectomy (CPM) decisions for breast cancer patients can be improved. Considering total health risks, not just contralateral breast cancer (CBC) risk, aids in making more informed choices about CPM.

More Related Videos

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.7K
Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
08:50

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

11.8K

Related Experiment Videos

Last Updated: Sep 6, 2025

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
13:35

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

2.9K
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.7K
Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
08:50

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

11.8K

Area of Science:

  • Oncology
  • Medical Decision Making
  • Biostatistics

Background:

  • Increasing trend of contralateral prophylactic mastectomy (CPM) in women with unilateral breast cancer.
  • Decreasing incidence of contralateral breast cancer (CBC) in recent years.
  • Existing models for CBC risk prediction aid CPM decisions.

Purpose of the Study:

  • To demonstrate the benefit of incorporating risks of regional/distant recurrence and non-breast cancer mortality into CPM decision-making.
  • To illustrate how a comprehensive risk assessment improves patient and physician choices regarding CPM.
  • To highlight the limitations of relying solely on CBC risk for CPM decisions.

Main Methods:

  • Utilized two published models for CBC risk assessment.
  • Incorporated published data on hazards of regional/distant recurrences and non-breast cancer mortality.
  • Calculated risk reductions from CPM for 10 hypothetical women across various breast cancer subtypes and risk factors.

Main Results:

  • CBC risk and overall health risks associated with CPM vary significantly by breast cancer subtype.
  • In some cases, CBC risk alone is sufficient for CPM decisions.
  • In other cases, considering total risk may lead women to decline CPM.

Conclusions:

  • Development of more informative tools for CPM decision-making is feasible.
  • Enhanced data is crucial for validating existing CBC risk models.
  • Better characterization of recurrence and mortality risks across diverse breast cancer subtypes is needed.